Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/447
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorCARVALHO, Jozelio Freire de-
dc.contributor.authorOLIVEIRA, Ricardo M. de-
dc.contributor.authorRODRIGUES, Carlos Ewerton Maia-
dc.contributor.authorGLEZER, Andrea-
dc.contributor.authorBONFA, Eloisa-
dc.contributor.authorPEREIRA, Rosa Maria Rodrigues-
dc.date.accessioned2013-07-30T14:41:48Z-
dc.date.available2013-07-30T14:41:48Z-
dc.date.issued2012-
dc.identifier.citationCLINICAL & DEVELOPMENTAL IMMUNOLOGY, article ID 232390, 5p, 2012-
dc.identifier.issn1740-2522-
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/447-
dc.description.abstractObjectives. The aim of this study was to investigate the HLA-G serum levels in Primary Antiphospholipid Syndrome (PAPS) patients, its impact on clinical and laboratory findings, and heparin treatment. Methods. Forty-four PAPS patients were age and gender matched with 43 controls. HLA-G serum levels were measured using an enzyme-linked immunosorbent assay (ELISA). Results. An increase in soluble HLA-G levels was found in patients compared to controls (3.35 (0 22.9) versus 1.1 (0 14), P = 0.017). There were no significant differences in HLA-G levels between patients with and without obstetric events, arterial thrombosis, venous thrombosis, or stroke. Sixty-six percent of patients were being treated with heparin. Interestingly, patients treated with heparin had higher HLA-G levels than ones who were not treated with this medication (5 (0-22.9) versus 1.8 (0-16) ng/mL, P = 0.038). Furthermore, patients on heparin who experienced obstetric events had a trend to increased HLA-G levels compared to patients who were not on heparin and did not have obstetric events (5.8 (0-22.9) versus 2 (0-15.2) ng/mL, P = 0.05). Conclusion. This is the first study to demonstrate that serum HLA-G levels are increased in APS patients. We also demonstrated that heparin increases HLA-G levels and may increase tolerance towards autoantigens.-
dc.language.isoeng-
dc.publisherHINDAWI PUBLISHING CORPORATION-
dc.relation.ispartofClinical & Developmental Immunology-
dc.rightsopenAccess-
dc.subject.othersystemic-lupus-erythematosus-
dc.subject.otherinflammatory myopathies-
dc.subject.othert-cells-
dc.subject.otherexpression-
dc.subject.otherantigen-
dc.subject.otherassociation-
dc.subject.otherpolymorphism-
dc.subject.othermolecule-
dc.subject.otherplasma-
dc.titleHeparin Increases HLA-G Levels in Primary Antiphospholipid Syndrome-
dc.typearticle-
dc.rights.holderCopyright HINDAWI PUBLISHING CORPORATION-
dc.identifier.doi10.1155/2012/232390-
dc.identifier.pmid22654952-
dc.subject.wosImmunology-
dc.type.categoryoriginal article-
dc.type.versionpublishedVersion-
hcfmusp.author.externalOLIVEIRA, Ricardo M. de:RDO Diagnost, Clin Lab, BR-01430001 Sao Paulo, Brazil-
hcfmusp.description.articlenumber232390-
hcfmusp.description.volume2012-
hcfmusp.origemWOS-
hcfmusp.origem.idWOS:000305016900001-
hcfmusp.origem.id2-s2.0-84862282190-
hcfmusp.publisher.cityNEW YORK-
hcfmusp.publisher.countryUSA-
hcfmusp.relation.referenceAractingi S, 2001, AM J PATHOL, V159, P71, DOI 10.1016/S0002-9440(10)61675-6-
hcfmusp.relation.referenceBaczyk D, 2006, PLACENTA, V27, P367, DOI 10.1016/j.placenta.2005.03.006-
hcfmusp.relation.referenceBaricordi Olavio R., 2008, Inflammation & Allergy Drug Targets, V7, P67, DOI 10.2174/187152808785107615-
hcfmusp.relation.referenceCarosella ED, 2001, TRENDS IMMUNOL, V22, P553, DOI 10.1016/S1471-4906(01)02007-5-
hcfmusp.relation.referenceFavier B, 2007, TISSUE ANTIGENS, V69, P207, DOI 10.1111/j.1399-0039.2006.00757.x-
hcfmusp.relation.referenceHarris EN, 1991, CLIN IMMUNOL NEWSL, V11, P33-
hcfmusp.relation.referenceKOVATS S, 1990, SCIENCE, V248, P220, DOI 10.1126/science.2326636-
hcfmusp.relation.referenceLeMaoult J, 2004, P NATL ACAD SCI USA, V101, P7064, DOI 10.1073/pnas.0401922101-
hcfmusp.relation.referenceRosadoab S, 2008, HUM IMMUNOL, V69, P9, DOI 10.1016/j.humimm.2007.11.001-
hcfmusp.relation.referenceMenier C, 2010, TISSUE ANTIGENS, V75, P201, DOI 10.1111/j.1399-0039.2009.01438.x-
hcfmusp.relation.referenceRebmann V, 2001, TISSUE ANTIGENS, V57, P15, DOI 10.1034/j.1399-0039.2001.057001015.x-
hcfmusp.relation.referenceRebmann V, 1999, TISSUE ANTIGENS, V53, P14, DOI 10.1034/j.1399-0039.1999.530102.x-
hcfmusp.relation.referenceRizzo R, 2008, TISSUE ANTIGENS, V71, P520, DOI 10.1111/j.1399-0039.2008.01037.x-
hcfmusp.relation.referenceTorres MI, 2004, INT IMMUNOL, V16, P579, DOI 10.1093/intimm/dxh061-
hcfmusp.relation.referenceVeit TD, 2009, LUPUS, V18, P424, DOI 10.1177/0961203308098187-
hcfmusp.relation.referenceVerbruggen LA, 2006, HUM IMMUNOL, V67, P561, DOI 10.1016/j.humimm.2006.03.023-
hcfmusp.relation.referenceWiendl H, 2003, HUM IMMUNOL, V64, P1050, DOI 10.1016/j.humimm.2003.07.001-
hcfmusp.relation.referenceWiendl H, 2000, ANN NEUROL, V48, P679, DOI 10.1002/1531-8249(200010)48:4<679::AID-ANA19>3.0.CO;2-V-
hcfmusp.relation.referenceWiendl H, 2005, BRAIN, V128, P2689, DOI 10.1093/brain/awh609-
hcfmusp.relation.referenceWilson WA, 1999, ARTHRITIS RHEUM, V42, P1309, DOI 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F-
hcfmusp.relation.referenceWisloff F, 2002, THROMB RES, V108, P263, DOI 10.1016/S0049-3848(02)00400-0-
hcfmusp.relation.referenceWu FX, 2009, LUPUS, V18, P1259, DOI 10.1177/0961203309345756-
dc.description.indexMEDLINE-
hcfmusp.lim.ref2012-
hcfmusp.citation.scopus7-
hcfmusp.scopus.lastupdate2022-05-20-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MCM
Departamento de Clínica Médica - FM/MCM

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC

Artigos e Materiais de Revistas Científicas - LIM/17
LIM/17 - Laboratório de Investigação em Reumatologia

Artigos e Materiais de Revistas Científicas - LIM/25
LIM/25 - Laboratório de Endocrinologia Celular e Molecular


Files in This Item:
File Description SizeFormat 
art_CARVALHO_Heparin_Increases_HLA_G_Levels_in_Primary_Antiphospholipid_2012.PDFpublishedVersion (English)104.33 kBAdobe PDFThumbnail
View/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.